Prostate Stents Market Size, Share & Industry Analysis, By Product Type (Permanent, Temporary), By Material Type (Metal, Plastic, others), By End User (Hospitals, Specialty Clinics, Research and Academic Institutes, Others) and Regional Forecast, 2024-2032

Prostate stents are used to open the surrounding of prostate urethra and bladder for the urine flow without any destruction. The blockage might be due to treatment of benign prostate hyperplasia, lower urinary tract symptoms, recurrent bulbar ureteral stricture, and others. Moreover, the blockage of urine flow might also be after the treatment of BPH which include transurethral needle ablation of the prostate (TUNA), transurethral resection of the prostate (TRUP), transurethral microwave thermotherapy, prostate cancer or radiation therapy. Hence these stents are useful in clearing the obstruction resulted from benign prostatic hyperplasia. Moreover, after the age of 40 years the prevalence increases about 8%-60% at the age of 90 years.

Furthermore, the prostate stents are of two types segmented into permanent stents and temporary stents. Wherein, temporary stents help in maintain urine flow and also allows voluntary urination.in addition to this they help patients in maintain normal urine flow after the procedure which usually influence negatively leading to prostatic swelling such as brachytherapy, cryotherapy, and others. Along with this, it also helps in detection of other urinary obstructions other than prostatic disorders. And permanent stents are used to reduce urinary obstruction secondary to BPH, RBUS, and others. Permanent stents are used only for the patients unable to take medication and undergo surgeries. Sometimes due to worsening of symptoms like migration, clot retention, and others may lead to removal of permanent stents. Currently there is only one FDA approved temporary stent named “The spanner” which helps in maintain of urine flow and only FDA approved permanent stent is “Urolume”.

Rise in cases of benign prostate hyperplasia, rise in prostate cancer, rise in geriatric population, rise in urbanization, and increase in procedures such as brachytherapy, cryotherapy and others are some of the factors driving the market. Furthermore, technological advancements by manufacturers is also triggering the growth of the market in the near future. In addition to this, robotic assisted minimal invasive procedures that help in early diagnosis, fast recovery and reduced length of hospital stay are positively influencing on the growth of prostate stents market. Moreover, rise in research and development activities coupled with mergers and acquisitions are also boosting the growth of the market.

However, stringent regulations, lack of technology penetration, the dearth of skilled professionals, risk of formation of bladder stones, and granulation tissues are hampering the growth of the market during the forecast period.

Key Players Covered:

The major companies in the global prostate stents market report include Protek Medical Products, Inc., Olympus Corporation, Pure Medical Devices, Cook, Coloplast Group, Medtronic, Smith and Nephew and Boston Scientific Corporation.

Key Insights:

• Prevalence of Prostate Disorders, Key Countries/ Region, 2018


• New Product Launches


• Technological Advancements of Prostate Stents


• Key Industry Developments

Regional Analysis:

Geographically, the prostate stents market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is dominating the market owing to the rise in the prevalence of prostate disorders, a rise in healthcare expenditure, and early adoption of technology. Europe is the second-largest contributor in the market owing to the rise in healthcare awareness and improved healthcare infrastructure. Asia Pacific is anticipated to witness lucrative growth owing to the rise in geriatric population, increase in healthcare awareness, and government initiatives, increase in research and development activities. Middle East and Africa are also expecting to experience lucrative growth owing to rise healthcare awareness.

Segmentation

Prostate Stents Industry Developments

• In April 2018, National Institute for Health Care Excellence has updated its guidance for using prostate artery embolization as a treatment of Benign Prostatic Hyperplasia